← Leaderboards
Pawel K. Mazur
Stanford University
$7,906,545
Attributed
$13,643,381
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,643,381 · 8
By mechanism
R01$12,616,946 · 6
R00$732,077 · 1
K99$294,358 · 1
Top collaborators
- Or P. Gozani13 shared
- Linghua Wang4 shared
- Mark T Bedford3 shared
Most similar at Stanford University
Same institution · by research overlap
- Eric Sebastian Fischer$7,372,602
- Jeffrey L Goldberg$19,761,316
- Michael S Kapiloff$15,217,225
- Julie Hyunjee Ko$80,371
- Paul A Khavari$40,653,927
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoMouse ModelPathway InteractionsMalignant NeoplasmsMolecularCellsOncogenicTumorMethyltransferaseMethylationTherapeutic TargetExperimental StudyMaintenanceSignal TransductionBiochemicalLysineCancer EtiologyCancer BiologyGrowthProteinsKras2 GeneTumor ProgressionMutationEnzymes
Grant awards (28)
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma$652,695
R01 · FY2025 · CA · contact PI
Mechanisms of action and therapeutic targeting of the CARM1-NFIB axis in small cell lung cancer$651,402
R01 · FY2025 · CA · contact PI
Role of NSD3 in regulation of cancer pathogenesis$644,553
R01 · FY2025 · CA · contact PI
Tumor cell lineage diversity and composition in gastric cancer progression and therapy resistance$642,253
R01 · FY2025 · CA
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma$620,060
R01 · FY2024 · CA · contact PI
Mechanisms of action and therapeutic targeting of the CARM1-NFIB axis in small cell lung cancer$618,833
R01 · FY2024 · CA · contact PI
Role of NSD3 in regulation of cancer pathogenesis$612,325
R01 · FY2024 · CA · contact PI
Tumor cell lineage diversity and composition in gastric cancer progression and therapy resistance$610,140
R01 · FY2024 · CA
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma$668,588
R01 · FY2023 · CA · contact PI
Role of NSD3 in regulation of cancer pathogenesis$660,709
R01 · FY2023 · CA · contact PI
Mechanisms of action and therapeutic targeting of the CARM1-NFIB axis in small cell lung cancer$651,402
R01 · FY2023 · CA · contact PI
Tumor cell lineage diversity and composition in gastric cancer progression and therapy resistance$629,409
R01 · FY2023 · CA
Role of the METTL13 Lysine Methyltransferase in Signaling and Cancer$450,894
R01 · FY2023 · CA
Role of SETD5 in Chromatin Regulation and Tumorigenesis$378,256
R01 · FY2023 · CA · contact PI
Tumor cell lineage diversity and composition in gastric cancer progression and therapy resistance$642,253
R01 · FY2022 · CA
Role of the METTL13 Lysine Methyltransferase in Signaling and Cancer$459,437
R01 · FY2022 · CA
Role of SETD5 in Chromatin Regulation and Tumorigenesis$378,555
R01 · FY2022 · CA · contact PI
Role of the METTL13 Lysine Methyltransferase in Signaling and Cancer$477,278
R01 · FY2021 · CA
Role of SETD5 in Chromatin Regulation and Tumorigenesis$386,462
R01 · FY2021 · CA · contact PI
Role of the METTL13 Lysine Methyltransferase in Signaling and Cancer$485,495
R01 · FY2020 · CA
Role of SETD5 in Chromatin Regulation and Tumorigenesis$386,532
R01 · FY2020 · CA · contact PI
Role of the METTL13 Lysine Methyltransferase in Signaling and Cancer$507,597
R01 · FY2019 · CA
Role of SETD5 in Chromatin Regulation and Tumorigenesis$401,818
R01 · FY2019 · CA · contact PI
The SMYD3-ERK5 signaling module in pancreatic cancer$238,818
R00 · FY2019 · CA · contact PI
The SMYD3-ERK5 signaling module in pancreatic cancer$244,259
R00 · FY2018 · CA · contact PI
The SMYD3-ERK5 signaling module in pancreatic cancer$249,000
R00 · FY2017 · CA · contact PI
The SMYD3-ERK5 signaling module in pancreatic cancer$147,179
K99 · FY2016 · CA · contact PI
The SMYD3-ERK5 signaling module in pancreatic cancer$147,179
K99 · FY2015 · CA · contact PI